ITGA6 Gene Epidermolysis Bullosa Junctional with Pyloric Atresia Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
Clinical Guidance: Complimentary telephonic post-test consultation with a DHA-licensed specialist to interpret your results.
Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.

Your genetic data is strictly protected under UAE PDPL (Federal Decree-Law No. 45 of 2021) and Federal Law No. 2 of 2019 concerning health information. All testing adheres to Federal Decree-Law No. 4 of 2016 on Medical Liability.

Test Overview & Methodology

This next-generation sequencing test precisely detects pathogenic mutations in the ITGA6 gene, confirming the diagnosis of epidermolysis bullosa junctionalis with pyloric atresia—a severe inherited blistering disorder. The assay empowers clinicians with definitive molecular data for prognosis, family planning, and targeted management.

Feature	Our ITGA6 NGS Test	Closest Alternative (Targeted Genotyping)
Precision	≥99.9% diagnostic sensitivity; full gene coverage	Limited to known hotspots; may miss novel variants
Methodology	Next Generation Sequencing (NGS) with advanced bioinformatics	Sanger sequencing or PCR‑based single‑site analysis
Turnaround Time	3–4 weeks	4–6 weeks (often with reflex testing)
Regulatory Compliance	DHA licensed, ISO 9001:2015 certified, PDPL compliant	Varies; may lack UAE‑specific certifications

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics, I understand the profound anxiety a suspected epidermolysis bullosa diagnosis brings. This NGS test offers families definitive answers, but results must be correlated with clinical findings. I encourage every patient to discuss the outcome with a genetic counsellor and never make therapy decisions in isolation.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Important Advisory

The results of this genetic test provide diagnostic information but must be interpreted in conjunction with clinical evaluation. Do not alter your medication or treatment plan without consulting your specialist.

Exclusion Criteria

Known active severe infection (e.g., sepsis) – defer phlebotomy until resolution.
Blood transfusion within the last 2 weeks (may interfere with DNA extraction quality).
Inability to provide informed consent – minors require an authorised guardian; mandatory pre‑test genetic counselling applies.
Patient unable to lie still or cooperate for venous blood draw without excessive risk.

Emergency Red Flags (After Sample Collection)

Seek immediate medical attention if you experience: severe bleeding or haematoma at the puncture site, signs of infection (redness, warmth, pus), or an unexpected allergic reaction to antiseptic.

Patient FAQ & Clinical Guidance

1. What is the clinical purpose of the ITGA6 gene NGS test?

The ITGA6 NGS test identifies disease‑causing mutations in the ITGA6 gene to confirm a diagnosis of junctional epidermolysis bullosa with pyloric atresia, enabling precise prognosis and management planning. It clarifies carrier status for family members and guides reproductive options in at‑risk couples.

2. How is the sample collected and what are the requirements?

A small sample of whole blood, extracted DNA, or a single drop of blood on an FTA card is collected by our DHA‑licensed mobile phlebotomist during a scheduled home visit. The patient must have completed a pre‑genetic counselling session, and no fasting is required.

3. When will I receive my results and how are they interpreted?

Results are reported within 3–4 weeks through a secure online portal, with an optional telephonic consultation to review findings. Interpretation categorises mutations as pathogenic, likely pathogenic, or variants of uncertain significance, and always requires correlation with clinical symptoms by your specialist.

UAE Regulatory & Data Privacy Adherence

Our testing processes comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.

Clinical & Logistical Metadata

Test Name	ITGA6 Gene Epidermolysis Bullosa Junctional with Pyloric Atresia Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks
Sample Type / Matrix	Whole blood, extracted DNA, or FTA card (blood spot)
Methodology Used	Next Generation Sequencing (NGS)
ICD-10-CM Code	Q81.8
LOINC Code	79252-5
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab Branding: DNA Labs UAE